Synektik Spólka Akcyjna company profile
Company profile
Synektik Spólka Akcyjna has 231 employees and is headquartered in Warsaw, Poland.
Synektik Spólka Akcyjna is known for radiopharmaceuticals used in oncology diagnostics, which it researches, produces and sells in Poland. The company also sells medical equipment for diagnostics, therapy and nuclear medicine, and develops IT solutions used in radiology. Its services for surgery, diagnostic imaging and nuclear medicine include maintenance of medical equipment, acceptance tests and specialist tests. Its range combines hardware, software, radiopharmaceuticals and technical services, and its activities are concentrated in Poland.
Founded in 2001 and headquartered in Warsaw, the company reported revenue of PLN 681.6 million in the fiscal year ended September 2025, an increase of 9.2% on the previous year, and net profit of PLN 102.9 million. It employs 231 people. All amounts are stated in Polish zloty.
Company facts
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Poland
- Headquarters
- ul. JOzefa Piusa Dziekonskiego 3, 00-728, Warsaw
- Employees
- 231
- Chief executive
- Cezary Kozanecki
- Founded
- 2001
- Fiscal year
- October - September
- Listing
- SNT · GPW
- Currency
- PLN
- ISIN
- PLSNKTK00019
- Website
- synektik.com.pl
Synektik Spólka Akcyjna and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Synektik Spólka AkcyjnaSNT | Poland | $647.15M | 231 | 23.3% | 15.9 |
| Revenio GroupREG1V | Finland | $428.87M | 765 | 14.1% | 25.1 |
| El.En.ELN | Italy | $1.44B | 1,459 | 14.7% | 20.7 |
| ChemoMetecCHEMM | Denmark | $1.75B | 174 | 49.1% | 59.9 |
| ElektaEKTA.B | Sweden | $2.27B | 3,996 | 9.2% | — |
| Medacta GroupMOVE | Switzerland | $2.41B | 2,273 | 15.2% | 27.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
